JP2015509931A - 医薬的な組み合わせ - Google Patents

医薬的な組み合わせ Download PDF

Info

Publication number
JP2015509931A
JP2015509931A JP2014556709A JP2014556709A JP2015509931A JP 2015509931 A JP2015509931 A JP 2015509931A JP 2014556709 A JP2014556709 A JP 2014556709A JP 2014556709 A JP2014556709 A JP 2014556709A JP 2015509931 A JP2015509931 A JP 2015509931A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
therapeutically effective
effective amount
solvated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014556709A
Other languages
English (en)
Japanese (ja)
Inventor
カルタビアーノ，ステファン
オールステイン，エリオット
マッカラム，スチュワート
Original Assignee
アルセレックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルセレックス，インコーポレイテッド filed Critical アルセレックス，インコーポレイテッド
Publication of JP2015509931A publication Critical patent/JP2015509931A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014556709A 2012-02-09 2013-02-08 医薬的な組み合わせ Pending JP2015509931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
US61/596,893 2012-02-09
PCT/US2013/025285 WO2013119910A1 (en) 2012-02-09 2013-02-08 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder

Publications (1)

Publication Number Publication Date
JP2015509931A true JP2015509931A (ja) 2015-04-02

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014556709A Pending JP2015509931A (ja) 2012-02-09 2013-02-08 医薬的な組み合わせ

Country Status (13)

Country Link
EP (1) EP2811989A1 (ko)
JP (1) JP2015509931A (ko)
KR (1) KR20150020160A (ko)
CN (1) CN104684549A (ko)
AR (1) AR089957A1 (ko)
AU (1) AU2013216864A1 (ko)
CA (1) CA2864173A1 (ko)
HK (1) HK1204966A1 (ko)
IL (1) IL234033A0 (ko)
PH (1) PH12014501814A1 (ko)
SG (1) SG11201404776PA (ko)
TW (1) TW201338772A (ko)
WO (1) WO2013119910A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2015358378A1 (en) 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (ko) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
NZ599233A (en) * 2009-10-07 2013-04-26 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Also Published As

Publication number Publication date
WO2013119910A1 (en) 2013-08-15
SG11201404776PA (en) 2014-09-26
EP2811989A1 (en) 2014-12-17
HK1204966A1 (en) 2015-12-11
PH12014501814A1 (en) 2014-11-24
AU2013216864A1 (en) 2014-09-11
AR089957A1 (es) 2014-10-01
KR20150020160A (ko) 2015-02-25
TW201338772A (zh) 2013-10-01
IL234033A0 (en) 2014-09-30
CA2864173A1 (en) 2013-08-15
CN104684549A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
JP6441267B2 (ja) 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
US9522129B2 (en) Pharmaceutical Combination
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
SG184387A1 (en) Methods of improving quality of sleep
JP2015509931A (ja) 医薬的な組み合わせ
US20200246292A1 (en) Pharmaceutical compositions and the treatment of overactive bladder
WO2016004056A1 (en) Pharmaceutical combinations
JP2012507484A (ja) αアドレナリン受容体拮抗薬と抗ムスカリン薬の併用
JP2010530867A (ja) うつ病の治療
JP2010522139A (ja) α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
CA2898279C (en) Use of phenoxypropylamine compounds to treat sleep disorders
KR20100040294A (ko) 전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물
WO2005007191A1 (ja) 医薬組成物
JP2005314347A (ja) 疼痛抑制剤
WO2007088473A2 (en) Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
KR20230061528A (ko) 구강 건조증의 치료에 사용하기 위한 화합물
WO2018197638A1 (en) Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141208